Jacobs Levy Equity Management, Inc Intellia Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

  • $24.7 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020
SELL
$17.47 - $24.93 $292,867 - $417,926
-16,764 Closed
0 $0
Q2 2020

Aug 17, 2020
SELL
$11.14 - $22.87 $675,908 - $1.39 Million
-60,674 Reduced 78.35%
16,764 $352,000
Q1 2020

May 15, 2020
BUY
$9.44 - $15.58 $423,091 - $698,280
44,819 Added 137.4%
77,438 $947,000
Q4 2019

Feb 14, 2020
BUY
$10.43 - $17.67 $340,216 - $576,377
32,619 New
32,619 $479,000

Others Institutions Holding NTLA

# of Institutions
317
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $835M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email